MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$13,054,000
EPS
-$1.05
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
36,839,000
0
0
Research and development
8,770,000
8,978,000
3,908,000
7,020,000
General and administrative
5,160,000
4,598,000
3,977,000
3,679,000
Total operating expenses
13,930,000
13,576,000
7,885,000
10,699,000
Operating (loss) income
-13,930,000
23,263,000
-7,885,000
-10,699,000
Other income (expense), net-Nonrelated Party
29,000
9,000
-70,000
-34,000
Other income (expense), net-Related Party
35,000
24,000
-47,000
-6,000
Interest income
812,000
838,000
865,000
399,000
Interest expense
-
-
1,000
5,000
Net (loss) income before income taxes and noncontrolling interest
-13,054,000
24,134,000
-7,138,000
-10,345,000
U.s. statutory tax benefit
-
-
-1,631,750*
-
Change in valuation allowance
-
-
1,731,250*
-
Tax credits
-
-
80,750*
-
Other
-
-
18,750*
-
Income tax provision
0
0
0
0
Net (loss) income before noncontrolling interest
-13,054,000
24,134,000
-7,138,000
-10,345,000
Less net loss attributable to noncontrolling interest
0
0
0
-1,647,000
Net (loss) income attributable to vtv therapeutics inc
-13,054,000
24,134,000
-7,138,000
-8,698,000
Basic EPS
-1.05
1.94
-0.671
-1.08
Diluted EPS
-1.05
1.65
-0.671
-1.08
Basic Average Shares
12,409,316
12,409,278
10,632,112
8,055,940
Diluted Average Shares
12,409,316
14,634,420
10,632,112
8,055,940
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net (loss) income
attributable to vtv...
-$13,054,000
(-115.91%↓ Y/Y)
Net (loss) income
before noncontrolling...
-$13,054,000
(-76.88%↓ Y/Y)
Net (loss) income
before income taxes and...
-$13,054,000
(-76.88%↓ Y/Y)
Interest income
$812,000
(195.27%↑ Y/Y)
Other income
(expense), net-Related...
$35,000
(-35.19%↓ Y/Y)
Other income
(expense), net-Nonrelated...
$29,000
(141.67%↑ Y/Y)
Operating (loss) income
-$13,930,000
(-80.42%↓ Y/Y)
Total operating
expenses
$13,930,000
(80.42%↑ Y/Y)
Research and development
$8,770,000
(113.75%↑ Y/Y)
General and
administrative
$5,160,000
(42.62%↑ Y/Y)
Buy us a coffee
vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (VTVT)